{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T09:01:47Z","timestamp":1792573307310,"version":"4.5.0"},"reference-count":90,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"unspecified","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["bmjonc"],"accepted":{"date-parts":[[2026,1,27]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:p>The treatment paradigm for deficient mismatch repair (dMMR) colorectal cancer (CRC) has evolved substantially in recent years. Universal mismatch repair testing and broad use of next-generation sequencing have increased the detection of dMMR tumours, which exhibit microsatellite instability-high (MSI-H), hypermutation and abundant neoantigens. The presence of dMMR\/MSI-H serves as a robust predictive biomarker for immune checkpoint inhibitor (ICI) therapy, which has demonstrated superior efficacy to cytotoxic chemotherapy in the metastatic setting and led to the first tumour-agnostic Food and Drug Administration approval in 2017 for metastatic dMMR\/MSI-H solid tumours. Recent evidence also supports the benefit of ICIs in non-metastatic dMMR CRC. Neoadjuvant immunotherapy has produced high rates of pathological response in both colon and rectal cancers. In locally advanced dMMR rectal cancer, ICI therapy has enabled omission of chemoradiation and surgery in most patients. In resected node-positive dMMR colon cancer, the addition of ICI therapy to chemotherapy has substantially improved disease-free survival, expanding its role earlier in the disease course. Despite these advances, the optimal treatment strategy for non-metastatic dMMR CRC remains undefined due to the lack of direct comparative studies. Importantly, a subset of patients derives limited or no benefit from ICIs despite dMMR\/MSI-H status, underscoring the need to further elucidate resistance mechanisms and to develop strategies to overcome them.<\/jats:p>","DOI":"10.1136\/bmjonc-2025-000980","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T07:00:17Z","timestamp":1771225217000},"page":"e000980","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Deficient mismatch repair\/microsatellite instability-high colorectal cancer: current treatment paradigms, limitations and future perspectives"],"prefix":"10.1136","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1266-7393","authenticated-orcid":false,"given":"Michael H","family":"Storandt","sequence":"first","affiliation":[{"name":"Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank A","family":"Sinicrope","sequence":"additional","affiliation":[{"name":"Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"Gastrointestinal Research Unit, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,2,15]]},"reference":[{"key":"2026021523001150000_5.1.e000980.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"2026021523001150000_5.1.e000980.2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0856"},{"key":"2026021523001150000_5.1.e000980.3","doi-asserted-by":"publisher","DOI":"10.1038\/nature11252"},{"key":"2026021523001150000_5.1.e000980.4","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.3390\/cancers13123063","article-title":"Microsatellite Instability in Colorectal Cancers: Carcinogenesis, Neo-Antigens, Immuno-Resistance and Emerging Therapies","volume":"13","author":"Randrian","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026021523001150000_5.1.e000980.5","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s00262-025-03980-x","article-title":"Microsatellite instability-high status as a pan-cancer biomarker for immunotherapy efficacy","volume":"74","author":"Landre","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"2026021523001150000_5.1.e000980.6","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-08-0512"},{"key":"2026021523001150000_5.1.e000980.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1714533"},{"key":"2026021523001150000_5.1.e000980.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0804588"},{"key":"2026021523001150000_5.1.e000980.9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.3452"},{"key":"2026021523001150000_5.1.e000980.10","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604867"},{"key":"2026021523001150000_5.1.e000980.11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.1825"},{"key":"2026021523001150000_5.1.e000980.12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0332"},{"key":"2026021523001150000_5.1.e000980.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400634"},{"key":"2026021523001150000_5.1.e000980.14","doi-asserted-by":"crossref","unstructured":"Sinicrope FA , Ou F-S , Arnold D , et al . Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC). J Clin Oncol 2025;43. doi:10.1200\/JCO.2025.43.17_suppl.LBA1","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA1"},{"key":"2026021523001150000_5.1.e000980.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699"},{"key":"2026021523001150000_5.1.e000980.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02848-4"},{"key":"2026021523001150000_5.1.e000980.17","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1001\/jamaoncol.2023.3323","article-title":"Neoadjuvant Immune Checkpoint Inhibitor Therapy for Localized Deficient Mismatch Repair Colorectal Cancer: A Review","volume":"9","author":"Emiloju","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026021523001150000_5.1.e000980.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402141"},{"key":"2026021523001150000_5.1.e000980.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02462"},{"key":"2026021523001150000_5.1.e000980.20","doi-asserted-by":"publisher","DOI":"10.1002\/jgc4.1546"},{"key":"2026021523001150000_5.1.e000980.21","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0012"},{"key":"2026021523001150000_5.1.e000980.22","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100120","article-title":"Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer","volume":"6","author":"Guyot D\u2019Asni\u00e8res De Salins","year":"2021","journal-title":"ESMO Open"},{"key":"2026021523001150000_5.1.e000980.23","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.5858\/arpa.2018-0201-OA","article-title":"Screening for Lynch Syndrome by Immunohistochemistry of Mismatch Repair Proteins: Significance of Indeterminate Result and Correlation With Mutational Studies","volume":"143","author":"Sarode","year":"2019","journal-title":"Arch Pathol Lab Med"},{"key":"2026021523001150000_5.1.e000980.24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/his.14233","article-title":"Identifying mismatch repair\u2010deficient colon cancer: near\u2010perfect concordance between immunohistochemistry and microsatellite instability testing in a large, population\u2010based series","volume":"78","author":"Loughrey","year":"2021","journal-title":"Histopathology"},{"key":"2026021523001150000_5.1.e000980.25","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0094-7"},{"key":"2026021523001150000_5.1.e000980.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.12.001"},{"key":"2026021523001150000_5.1.e000980.27","doi-asserted-by":"crossref","first-page":"103300","DOI":"10.1016\/j.labinv.2024.103300","article-title":"1066 NGS-MSI and IHC-MMR Concordance in Endometrial and Colorectal Cancers","volume":"105","author":"Santoro","year":"2025","journal-title":"Laboratory Investigation"},{"key":"2026021523001150000_5.1.e000980.28","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1200\/JCO.2023.41.4_suppl.30","article-title":"Analysis of concordance between microsatellite instability by next generation sequencing (NGS-MSI) and mismatch repair deficiency by immunohistochemistry (IHC-MMR) in >28,000 colorectal tumors","volume":"41","author":"Ali-Fehmi","year":"2023","journal-title":"JCO"},{"key":"2026021523001150000_5.1.e000980.29","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1200\/JCO.2023.41.4_suppl.199","article-title":"Characterizing the genomic landscape of POLE\/POLD1 -mutated colorectal adenocarcinoma","volume":"41","author":"Coston","year":"2023","journal-title":"JCO"},{"key":"2026021523001150000_5.1.e000980.30","doi-asserted-by":"crossref","DOI":"10.1200\/PO.21.00267","article-title":"Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers","volume":"6","author":"Garmezy","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"2026021523001150000_5.1.e000980.31","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2015.12"},{"key":"2026021523001150000_5.1.e000980.32","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2503"},{"key":"2026021523001150000_5.1.e000980.33","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3202"},{"key":"2026021523001150000_5.1.e000980.34","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1200\/JCO.2024.42.3_suppl.184","article-title":"Molecular and clinical characteristics of POLE\/POLD1 alterations among patients with colorectal cancer","volume":"42","author":"Syed","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026021523001150000_5.1.e000980.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.03.009"},{"key":"2026021523001150000_5.1.e000980.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032709"},{"key":"2026021523001150000_5.1.e000980.37","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29072"},{"key":"2026021523001150000_5.1.e000980.38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02538"},{"key":"2026021523001150000_5.1.e000980.39","doi-asserted-by":"crossref","unstructured":"Tougeron D , Mouillet G , Trouilloud I , et al . Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study. J Natl Cancer Inst 2016;108. doi:10.1093\/jnci\/djv438","DOI":"10.1093\/jnci\/djv438"},{"key":"2026021523001150000_5.1.e000980.40","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.01600"},{"key":"2026021523001150000_5.1.e000980.41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00046"},{"key":"2026021523001150000_5.1.e000980.42","doi-asserted-by":"crossref","first-page":"S1217","DOI":"10.1016\/j.annonc.2024.08.2263","article-title":"LBA24 Neoadjuvant immunotherapy in locally advanced MMR-deficient colon cancer: 3-year disease-free survival from NICHE-2","volume":"35","author":"Chalabi","year":"2024","journal-title":"Ann Oncol"},{"key":"2026021523001150000_5.1.e000980.43","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1038\/s41591-024-03250-w","article-title":"Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial","volume":"30","author":"de Gooyer","year":"2024","journal-title":"Nat Med"},{"key":"2026021523001150000_5.1.e000980.44","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S2468-1253(21)00348-4","article-title":"Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial","volume":"7","author":"Hu","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026021523001150000_5.1.e000980.45","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.22.01351","article-title":"Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High\/Deficient Mismatch Repair Solid Tumors","volume":"41","author":"Ludford","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026021523001150000_5.1.e000980.46","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1470-2045(24)00203-1","article-title":"Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study","volume":"25","author":"Yu","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026021523001150000_5.1.e000980.47","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA3504","article-title":"NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumour mutation burden for high risk stage 2 or stage 3 deficient-MMR\/MSI-high colorectal cancer","volume":"42","author":"Shiu","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026021523001150000_5.1.e000980.48","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JCO.2025.43.4_suppl.19","article-title":"Single-cycle neoadjuvant pembrolizumab in patients with stage I-III MMR-deficient colon cancer: Final analysis of the RESET-C study","volume":"43","author":"Qvortrup","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026021523001150000_5.1.e000980.49","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103499","article-title":"Neoadjuvant PD-1 blockade with toripalimab with or without celecoxib for patients with mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): long-term outcomes of a single-centre, parallel-group, non-comparative, randomised phase 2 trial","volume":"88","author":"Shen","year":"2025","journal-title":"eClinicalMedicine"},{"key":"2026021523001150000_5.1.e000980.50","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1540751","article-title":"The neoadjuvant immunotherapy for non-metastatic mismatch repair-deficient colorectal cancer: a systematic review","volume":"16","author":"Cui","year":"2025","journal-title":"Front Immunol"},{"key":"2026021523001150000_5.1.e000980.51","unstructured":"Benson AB , Venook AP , Adam M , et al . Colon Cancer, Version 4.2025, NCCN Clinical Practice Guidelines in Oncology. NCCN; 2025."},{"key":"2026021523001150000_5.1.e000980.52","doi-asserted-by":"crossref","first-page":"110396","DOI":"10.1016\/j.ejrad.2022.110396","article-title":"Colon cancer microsatellite instability influences computed tomography assessment of regional lymph node morphology and diagnostic performance","volume":"154","author":"Kim","year":"2022","journal-title":"Eur J Radiol"},{"key":"2026021523001150000_5.1.e000980.53","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602534"},{"key":"2026021523001150000_5.1.e000980.54","doi-asserted-by":"crossref","first-page":"112329","DOI":"10.1016\/j.ejrad.2025.112329","article-title":"Prediction of histopathology in colon cancer by multidetector computed tomography stratified by tumour side and microsatellite status: A national register study","volume":"191","author":"Casarin","year":"2025","journal-title":"Eur J Radiol"},{"key":"2026021523001150000_5.1.e000980.55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713709"},{"key":"2026021523001150000_5.1.e000980.56","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.3_suppl.TPS240","article-title":"AZUR-2, a phase III, open-label, randomized study of perioperative dostarlimab monotherapy vs standard of care in previously untreated patients with T4N0 or stage III dMMR\/MSI-H resectable colon cancer","volume":"42","author":"Starling","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026021523001150000_5.1.e000980.57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211437"},{"key":"2026021523001150000_5.1.e000980.58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402604"},{"key":"2026021523001150000_5.1.e000980.59","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009722","article-title":"Immune checkpoint blockade: timing is everything","volume":"12","author":"Sinicrope","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026021523001150000_5.1.e000980.60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201445"},{"key":"2026021523001150000_5.1.e000980.61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404512"},{"key":"2026021523001150000_5.1.e000980.62","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103929","article-title":"Curative immune checkpoint inhibitors therapy in patients with mismatch repair-deficient locally advanced rectal cancer: a real-world observational study","volume":"9","author":"Tosi","year":"2024","journal-title":"ESMO Open"},{"key":"2026021523001150000_5.1.e000980.63","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/DCR.0000000000001135","article-title":"Can Endorectal Ultrasound, MRI, and Mucosa Integrity Accurately Predict the Complete Response for Mid-Low Rectal Cancer After Preoperative Chemoradiation? A Prospective Observational Study from a Single Medical Center","volume":"61","author":"Liu","year":"2018","journal-title":"Dis Colon Rectum"},{"key":"2026021523001150000_5.1.e000980.64","doi-asserted-by":"crossref","first-page":"5964","DOI":"10.3748\/wjg.v19.i36.5964","article-title":"How reliable is current imaging in restaging rectal cancer after neoadjuvant therapy?","volume":"19","author":"Nardi","year":"2013","journal-title":"WJG"},{"key":"2026021523001150000_5.1.e000980.65","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/codi.16341","article-title":"Endoscopy and MRI for restaging early rectal cancer after neoadjuvant treatment","volume":"25","author":"Stijns","year":"2023","journal-title":"Colorectal Dis"},{"key":"2026021523001150000_5.1.e000980.66","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2625"},{"key":"2026021523001150000_5.1.e000980.67","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02107"},{"key":"2026021523001150000_5.1.e000980.68","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00197-8"},{"key":"2026021523001150000_5.1.e000980.69","doi-asserted-by":"crossref","first-page":"S1573","DOI":"10.1016\/j.annonc.2025.09.040","article-title":"LBA29 Nivolumab plus ipilimumab vs nivolumab monotherapy for microsatellite instability-high\/mismatch repair-deficient (MSI-H\/dMMR) metastatic colorectal cancer (mCRC): New results from CheckMate 8HW","volume":"36","author":"Lonardi","year":"2025","journal-title":"Ann Oncol"},{"key":"2026021523001150000_5.1.e000980.70","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS3647","article-title":"Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6\/bevacizumab\/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)\u2014NRG-GI004\/SWOG-S1610","volume":"40","author":"Rocha Lima","year":"2022","journal-title":"JCO"},{"key":"2026021523001150000_5.1.e000980.71","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2267"},{"key":"2026021523001150000_5.1.e000980.72","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-024-03825-z","article-title":"Genomic and molecular alterations associated with primary resistance to immune checkpoint inhibitors","volume":"73","author":"Malhotra","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"2026021523001150000_5.1.e000980.73","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.06.064"},{"key":"2026021523001150000_5.1.e000980.74","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-20-0308"},{"key":"2026021523001150000_5.1.e000980.75","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112638","article-title":"Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers","volume":"13","author":"Amodio","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026021523001150000_5.1.e000980.76","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02691"},{"key":"2026021523001150000_5.1.e000980.77","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.0400","article-title":"Association Between Survival and Metastatic Site in Mismatch Repair-Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab","volume":"6","author":"Saberzadeh-Ardestani","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026021523001150000_5.1.e000980.78","doi-asserted-by":"crossref","first-page":"113495","DOI":"10.1016\/j.ejca.2023.113495","article-title":"Immunotherapy in mismatch repair-deficient metastatic colorectal cancer - Outcome and novel predictive markers","volume":"198","author":"Stemmer","year":"2024","journal-title":"Eur J Cancer"},{"key":"2026021523001150000_5.1.e000980.79","doi-asserted-by":"crossref","first-page":"113433","DOI":"10.1016\/j.ejca.2023.113433","article-title":"Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting","volume":"196","author":"Saberzadeh-Ardestani","year":"2024","journal-title":"Eur J Cancer"},{"key":"2026021523001150000_5.1.e000980.80","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1131-x"},{"key":"2026021523001150000_5.1.e000980.81","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.18416","article-title":"Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1\/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases","volume":"4","author":"Wang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026021523001150000_5.1.e000980.82","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010424","article-title":"Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitors","volume":"13","author":"Taieb","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026021523001150000_5.1.e000980.83","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuno.2021.100008"},{"key":"2026021523001150000_5.1.e000980.84","doi-asserted-by":"crossref","unstructured":"Bass C , Ntelemis F , Schmidt J , et al . H&E-based MSI\/MMR testing with AI in colorectal cancer: a multi-centred blinded evaluation. npj Digit Med 2025;9. doi:10.1038\/s41746-025-02218-5","DOI":"10.1038\/s41746-025-02218-5"},{"key":"2026021523001150000_5.1.e000980.85","doi-asserted-by":"crossref","unstructured":"Feng X , Yin W , Ye Q , et al . Deepath-MSI: a clinic-ready deep learning model for microsatellite instability detection in colorectal cancer using whole-slide imaging. npj Precis Onc 2025;9. doi:10.1038\/s41698-025-01094-2","DOI":"10.1038\/s41698-025-01094-2"},{"key":"2026021523001150000_5.1.e000980.86","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1053\/j.gastro.2022.08.025","article-title":"Quantitative Pathologic Analysis of Digitized Images of Colorectal Carcinoma Improves Prediction of Recurrence-Free Survival","volume":"163","author":"Pai","year":"2022","journal-title":"Gastroenterology"},{"key":"2026021523001150000_5.1.e000980.87","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32998-8"},{"key":"2026021523001150000_5.1.e000980.88","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1158\/1078-0432.CCR-24-3720","article-title":"Artificial Intelligence Algorithm Predicts Response to Immune Checkpoint Inhibitors","volume":"31","author":"Fa\u2019ak","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026021523001150000_5.1.e000980.89","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.hlife.2025.02.001","article-title":"Machine learning approach to predict prognosis and immunotherapy responses in colorectal cancer patients","volume":"3","author":"Liu","year":"2025","journal-title":"hLife"},{"key":"2026021523001150000_5.1.e000980.90","doi-asserted-by":"crossref","first-page":"11795549231220320","DOI":"10.1177\/11795549231220320","article-title":"Artificial Intelligence Applications in the Treatment of Colorectal Cancer: A Narrative Review","volume":"18","author":"Yang","year":"2024","journal-title":"Clin Med Insights Oncol"}],"container-title":["BMJ Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjonc-2025-000980","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T07:00:22Z","timestamp":1771225222000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjoncology.bmj.com\/lookup\/doi\/10.1136\/bmjonc-2025-000980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":90,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2,15]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1136\/bmjonc-2025-000980"],"URL":"https:\/\/doi.org\/10.1136\/bmjonc-2025-000980","relation":{},"ISSN":["2752-7948"],"issn-type":[{"value":"2752-7948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}